דילוג לתוכן הראשי
xMedica

NCT06056830ClinicalTrials.gov

Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy: A Prospective, Single-arm, Multi-center, Blinded-review, Phase 3 Diagnostic Performance Study

מגייסמקבל משתתפים כעת, לפי רשומת המרשם.
יצירת קשר עם המחקר

בקצרה

The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.

שלב 3דרושים 383 משתתפים34 אתרים3 מדינות

קטגוריות

רשום במרשם אחד

מחקר יחיד יכול להיות רשום בכמה מרשמים. אנו מציגים אותו פעם אחת ומקשרים לכל רשומה שברשותנו.

מידע הניסוי מוצג כפי שפורסם על ידי המרשם, בשפת המקור שלו.

מתעניינים במחקר הזה?

התחברות או צרו חשבון כדי לרשום את התעניינותכם ולעקוב אחר המחקר הזה.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2023-09-28; recorded start 2023-12-21
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Not stated: Participants are not randomly assignedAllocation is recorded as non-randomised
  • Not stated: A comparison group is not stated in the registry recordThe record describes a single study arm
  • Not stated: Open label (no blinding)Masking is recorded as none (open label)
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 4 other studies in this databaseCounted from the lead sponsor named in the record (Clarity Pharmaceuticals Ltd)
  • Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
  • The record lists 2 conditions.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourEXPLORATORY

An exploratory-stage design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation0/20

    Allocation not stated in the record

  • Blinding0/20

    Open-label

  • Control arm0/15

    No comparator arm stated in the record

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 31 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study, international in scope: 383 participants (target), run at 34 sites, across 3 countries.

How this score is built
  • Enrolment25/40

    383 participants (target)

  • Site count18/25

    31 sites

  • Country count7/15

    3 countries

  • Planned duration8/10

    Planned over about 33 months

  • Sponsor scale2/10

    Clarity Pharmaceuticals Ltd has led 5 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

תקציר

The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.

מצבים רפואיים

  • Prostate Cancer
  • Prostatic Neoplasms

זכאות

זכאות
מיןזכר
גילאים18 Yearsללא מקסימום
מתנדבים בריאיםלא

זכאות כפי שנכתבה במרשם

Inclusion Criteria: * At least 18 years of age. * Signed informed consent. * Untreated, histologically confirmed adenocarcinoma of the prostate. * High-risk or greater PC defined by National Comprehensive Cancer Network Guidelines Version 1.202327 (clinical stage ≥T3a, or Grade Group ≥4, or PSA \>20 ng/mL). * Patients electing to undergo RP with PLND. Exclusion Criteria: * Administration of any high energy (\>300 KeV) gamma-emitting radioisotope within 5 physical half-lives prior to Day 1. * Known or expected hypersensitivity to 64Cu-SAR-bisPSMA or any of its components. * Patients with known predominant small cell or neuroendocrine PC.

זכאות במשפטים פשוטים

הקריטריונים של רשומה זו טרם פורקו למשפטים נפרדים. טקסט המרשם שלמעלה שלם והוא הגרסה המחייבת.

תכנון המחקר

תכנון המחקר
סוג המחקרהתערבותי
שלבשלב 3
הקצאהלא רלוונטי
מודל ההתערבותSINGLE_GROUP
מטרה ראשיתDIAGNOSTIC
הסתרהNONE (0)
גיוסדרושים 383 משתתפים

נותן חסות ושותפים

  • Clarity Pharmaceuticals Ltd נותן חסות

זרועות והתערבויות

  • 64Cu-SAR-bisPSMAEXPERIMENTAL

    200MBq 64Cu-SAR-bisPSMA.

התערבויות

  • תרופה 64Cu-SAR-bisPSMA

    All Patients will receive a single administration, a bolus injection of 200MBq 64Cu-SAR-bisPSMA.

מדדי תוצאה

  1. מדד תוצאה ראשוני

    Diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases

    Independent primary endpoints for Day 1 and Day 2 PET: Co-primary endpoint of sensitivity and specificity of 64Cu-SAR-bisPSMA PET to detect Prostate Cancer within the pelvic lymph nodes compared to the Standard of Truth.

    מסגרת זמן Up to 16 weeks

  2. מדד תוצאה משני

    Safety and tolerability of 64Cu-SAR-bisPSMA

    Incidence and severity of treatment-emergent AEs and SAEs following administration of 64Cu-SAR-bisPSMA

    מסגרת זמן Up to 16 weeks

  3. מדד תוצאה משני

    Consistency of 64Cu-SAR-bisPSMA PET/CT interpretations for the three central readers

    Inter-reader reliability of agreement estimated with a multiple-reader kappa statistic

    מסגרת זמן Up to 16 weeks

  4. מדד תוצאה משני

    PPV and NPV of 64Cu-SAR-bisPSMA PET to detect PC within the pelvic LNs

    PPV and NPV of 64Cu-SAR-bisPSMA PET to detect PC within the pelvic LNs compared to the Standard of Truth

    מסגרת זמן Up to 16 weeks

  5. מדד תוצאה משני

    Ability of 64Cu-SAR-bisPSMA PET to detect Prostate Cancer

    Sensitivity of 64Cu-SAR-bisPSMA PET to detect PC within the prostate gland compared to the Standard of Truth

    מסגרת זמן Up to 16 weeks

  6. מדד תוצאה משני

    Diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases without subregion matching

    Sensitivity and specificity of 64Cu-SAR-bisPSMA PET to detect PC within the pelvic LNs compared to the Standard of Truth, without the requirement of subregion (Left or Right) matching between 64Cu-SAR-bisPSMA PET and Standard of Truth

    מסגרת זמן Up to 16 weeks

תאריכים

תאריכים
תאריך התחלה21 בדצמבר 2023 (בפועל)
סיום ראשוני1 בספטמבר 2026 (משוער)
סיום1 בספטמבר 2026 (משוער)
פורסם לראשונה28 בספטמבר 2023 (בפועל)
עודכן לאחרונה11 בספטמבר 2026
התוצאות פורסמולא צוין ברשומת המרשם
המצב אומת לאחרונהספטמבר 2026

בפועל פירושו שהאירוע התרחש. משוער פירושו שנותן החסות צופה אותו. שתי המשמעויות שונות זו מזו.

מיקומים

34 אתרים מגייסים

Australia

Australia
מתקןעירמדינה או אזורמצב
Fiona Stanley HospitalMurdochWestern Australiaמגייס
RAMSAY HEALTH CARE AUSTRALIA PTY LIMITED (ABN 36 003 184 889) trading as Hollywood Private HospitalNedlandsWestern Australiaמגייס
St. Vincent's SydneySydneyNew South Walesמגייס
Princess Alexandra HospitalWoolloongabbaQueenslandמגייס

Puerto Rico

Puerto Rico
מתקןעירמדינה או אזורמצב
Pan American Center for Oncology Trials, LLC - CiudadelaSan Juanמגייס

United States

United States
מתקןעירמדינה או אזורמצב
Albany Medical College, Department of UrologyAlbanyNew Yorkמגייס
Urology Austin, PLLC - Research DepartmentAustinTexasמגייס
University of Alabama Birmingham HospitalBirminghamAlabamaמגייס
University of Texas Southwestern Medical CenterDallasTexasמגייס
Urology Clinics of North TexasDallasTexasמגייס
Duke University Medical CenterDurhamNorth Carolinaמגייס
NorthShore University Health System, Glenbrook HospitalGlenviewIllinoisמגייס
BAMF HealthGrand RapidsMichiganמגייס
Corewell HealthGrand RapidsMichiganמגייס
Indiana University School of MedicineIndianapolisIndianaמגייס
Mayo Clinic- JacksonvilleJacksonvilleFloridaמגייס
Arkansas Urology Research Center, LLCLittle RockArkansasמגייס
Greater Los Angeles VA Medical CenterLos AngelesCaliforniaמגייס
Urology Group of Southern CaliforniaLos AngelesCaliforniaמגייס
University of WisconsinMadisonWisconsinמגייס
Biogenix Molecular, LLCMiamiFloridaמגייס
Intermountain HealthMurrayUtahמגייס
Carolina Urologic Research CenterMyrtle BeachSouth Carolinaמגייס
Urology Associates of NashvilleNashvilleTennesseeמגייס
Mount Sinai Doctors Urology Faculty PracticeNew YorkNew Yorkמגייס
XCancer Omaha LLCOmahaNebraskaמגייס
UC Irvine HealthOrangeCaliforniaמגייס
Mayo Clinic- PhoenixPhoenixArizonaמגייס
Mayo Clinic- RochesterRochesterMinnesotaמגייס
The Urology PlaceSan AntonioTexasמגייס
Oregon UrologySpringfieldOregonמגייס
Stanford University Medical CenterStanfordCaliforniaמגייס
Urologic SpecialistsTulsaOklahomaמגייס
Wichita Urology GroupWichitaKansasמגייס

מסמכי המחקר

לא צורפו מסמכים ברשומת מרשם זו.

שינויים לאורך זמן

  1. 11 בספטמבר 2026

    אתר נוסף

    3 sites added (34 total)

    3134